Skip to content
Screener

Journey Medical Corporation DERM Q2 2025 earnings

Reported August 12, 2025 · After market close

Revenue$15.0MMiss by $3.9M
EPS-$0.16Miss by $0.09
Revenue estimate$18.9M
EPS estimate-$0.07

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$21.9M
EPS estimate$0.02

Financials

Q2 2025

Income statement

See full
Revenue$15.0M+1.0%
Gross profit$10.1M+21.1%
Operating income-$2.9M+1.7%
Net income-$3.8M-12.9%
EPS (diluted)-$0.16+5.9%

Balance sheet

See full
Cash & equivalents$20.3M-15.1%
Total debt$25.3M+27.6%
Total equity$19.2M+70.4%
Total assets$81.2M+24.5%

Cash flow

See full
Operating cash flow-$942.0K+81.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$148.63M+33.4%
Enterprise value$153.61M+43.1%
P/S2.6×+1.2×

Profitability

See full
Gross margin69.4%-2.2pp

Returns & leverage

See full
Debt / equity1.3×-0.4×
Current ratio1.3×-0.1×

Segments

By product

See full
Qbrexza$6.9M+1.7%
Accutane$3.4M-40.6%
Emrosi$2.8M—
Other Legacy$735.0K+1.2%

By segment

See full
Dermatological$15.0M+7.0%

FAQ

When did Journey Medical Corporation report Q2 2025 earnings?
Journey Medical Corporation (DERM) reported Q2 2025 earnings on August 12, 2025 after market close.
What were Journey Medical Corporation's Q2 2025 revenue and EPS?
Journey Medical Corporation reported revenue of $15.0M and eps of $-0.16 for Q2 2025.
Did Journey Medical Corporation beat estimates in Q2 2025?
Revenue missed the consensus estimate of $18.9M by $3.9M. EPS missed the consensus estimate of $-0.07 by $0.09.
How did Journey Medical Corporation's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.0% from $14.9M a year earlier and eps grew 5.9% from $-0.17.
Where can I find Journey Medical Corporation's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-076825) and the 10-Q periodic report (0001410578-25-001703) directly on SEC EDGAR. The filing index links above go to sec.gov.